Trade name Brukinsa
Pregnancy category AU: 3
Routes of administration By mouth
Drug class Bruton’s tyrosine kinase (BTK) inhibitor
Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL).
Indicated for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy, for the treatment of Waldenström’s macroglobulinemia, for the treatment of adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen, And for chronic lymphocytic leukemia or small lymphocytic lymphoma.
FDA has granted accelerated approval to zanubrutinib, in combination with obinutuzumab, for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
The most common adverse effects (≥30%) are: neutropenia, upper respiratory tract infection, thrombocytopenia, hemorrhage and musculoskeletal pain.
Administered orally at 160 mg twice daily or 320 mg once daily.